Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks

NCT00467402 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00467402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00467402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2007
Completion date
Not reported
Enrollment
644 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder